Exploring the clinical utility of Oncotype DX in ER+/HER2-, N0 and N1 breast cancer patients: Insights from a Romanian cohort

被引：0

作者：

Blidaru, A. ^{[1
]}

Zob, D. ^{[2
]}

Schenker, M. ^{[3
]}

Onisim, A. ^{[4
]}

Bodale, C. ^{[5
]}

Curca, R. ^{[6
]}

Negru, S. ^{[7
]}

Oprean, C. ^{[7
]}

Curescu, P. ^{[8
]}

Gafton, B. ^{[9
]}

Volovat, S. ^{[9
]}

Mihaila, R. ^{[2
]}

Filip, G. ^{[10
]}

Median, D. ^{[11
]}

Dediu, M. ^{[12
]}

Chetroiu, D. ^{[13
]}

Pantelimon, I. ^{[14
]}

Costovici, C. ^{[15
]}

Viisoreanu, C. G. ^{[16
]}

Titirez, V. ^{[17
]}

Mateescu, D. ^{[17
]}

Gal, C. ^{[17
]}

Vremes, G. ^{[18
]}

Stanculeanu, D. -L. ^{[1
]}

Tsoulos, N. ^{[19
]}

Kapetsis, G. ^{[19
]}

Giannoulakis, S. ^{[19
]}

Sires, A.

Chirnogea, A. ^{[20
]}

Maxim, A. -I. ^{[20
]}

Iorga, P. ^{[21
]}

Jinga, D. -C. ^{[22
]}

Nitipir, C. ^{[23
]}

机构：

[1] Alexandru Trestioreanu Inst, Bucharest, Romania

[2] Bucharest Oncol Inst, Bucharest, Romania

[3] St Nectarie Oncol Ctr, Craiova, Romania

[4] Medisprof Cluj Napoca, Cluj Napoca, Romania

[5] Amethyst Cluj Napoca, Cluj Napoca, Romania

[6] Elysee Alba Iulia, Alba Iulia, Romania

[7] OncoHelp Timisoara, Timisoara, Romania

[8] Timisoara Municipal Hosp, Timisoara, Romania

[9] Reg Inst Oncol Iasi, Iasi, Romania

[10] Ponderas Acad Hosp Regina Maria, Bucharest, Romania

[11] FILANTROPIA Clin Hosp Bucharest, Bucharest, Romania

[12] Provita Med Grp, Bucharest, Romania

[13] Bucharest Univ Emergency Hosp, Bucharest, Romania

[14] Clin Hosp Dr Ion Cantacuzino, Bucharest, Romania

[15] CMDTAMP Bucharest, Bucharest, Romania

[16] MedLife Breast Inst, Bucharest, Romania

[17] Euroclin Hosp Regina Maria, Bucharest, Romania

[18] MedLife Titan Hosp, Bucharest, Romania

[19] Genekor SA, Athens, Greece

[20] Fundeni Clin Inst Bucharest, Bucharest, Romania

[21] Clin Emergency Hosp Bucharest, Bucharest, Romania

[22] Neolife Clin Bucharest, Bucharest, Romania

[23] Agrippa Ionescu Hosp, Bucharest, Romania

来源：

BREAST | 2025年 / 80卷

关键词：

D O I：

10.1016/j.breast.2025.103934

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P051

引用

页数：2

共 50 条

[31] Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy?
Jwa, Eunjin
Shin, Kyung Hwan
Lim, Hyeon Woo
Jung, So-Youn
Lee, Seeyoun
Kang, Han-Sung
Lee, EunSook
Park, Young Hee
PLOS ONE, 2015, 10 (12):
[32] German multicentre decision impact study of Oncotype DX recurrence score (RS) on adjuvant treatment in estrogen receptor positive (ER plus ) node negative (N0) and node positive (N plus ) early breast cancer
Blohmer, J. -U.
Kuehn, T.
Rezai, M.
Kuemmel, S.
Warm, M.
Eggemann, H.
Friedrichs, K.
Eiermann, W.
BREAST, 2011, 20 : S46 - S46
[33] Can chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?
Lee, Juhyeon
Park, Chan Sub
Oh, Jeong Hun
Park, In-Chul
Seong, Min-Ki
Noh, Woo Chul
Kim, Hyun-Ah
ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2023, 105 (01) : 31 - 36
[34] HER2/NEU OVEREXPRESSION IN pT1a OR pT1b, N0, M0 BREAST CANCER
Petroni, S.
Asselti, M.
Giotta, F.
Quero, C.
D'Amico, C.
Marzano, A. L.
Daprile, R.
Salvatore, C.
Colucci, G.
Simone, G.
CANCER TREATMENT REVIEWS, 2010, 36 : S103 - S103
[35] Utilization of adjuvant trastuzumab for T1a,b N0 HER2+breast cancer in Ontario.
Eisen, Andrea
Yeung, Lyndee
Gavura, Scott
Brown, Zachary M.
Trudeau, Maureen E.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[36] Prediction Model for Malignant N1, N2 or N3 Nodal Disease Relative to N0 in Patients with Non-Small Cell Lung Cancer
Martinez-Zayas, G.
Almeida, F. A.
Simoff, M. J.
Thiboutot, J.
Molina Garcia, S.
Young, B. P.
Diaz-Mendoza, J.
Yu, D. H.
Sagar, A. S.
Cicenia, J. C.
Debiane, L.
Yarmus, L. B.
Grosu, H. B.
Sethi, S.
Feller-Kopman, D. J.
Casal, R. F.
Gildea, T. R.
Lee, H. J.
Eapen, G. A.
Machuzak, M.
Arain, M. H.
Jimenez, C. A.
Noor, L. Z.
Baghaie, S.
Song, J.
Li, L.
Ost, D. E.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[37] The significance of Oncotype DX recurrence score in T1-2N1M0 ER positive HER2 negative breast cancer: An analysis combined with the prognostic stage in the updated AJCC 8th edition
Chen, H.
Wang, M.
Zhang, P.
Zhang, M.
Wu, K.
CANCER RESEARCH, 2019, 79 (04)
[38] Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (≤2 cm) Non-Small Cell Lung Cancer
Robinson, Eric M.
Ilonen, Ilkka K.
Tan, Kay See
Plodkowski, Andrew J.
Bott, Matthew
Bains, Manjit S.
Adusumilli, Prasad S.
Park, Bernard J.
Rusch, Valerie W.
Jones, David R.
Huang, James
ANNALS OF THORACIC SURGERY, 2020, 109 (01): : 270 - 276
[39] Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic
Dowsett, Mitch
Ellis, Matthew J.
Dixon, J. Michael
Gluz, Oleg
Robertson, John
Kates, Ronald
Suman, Vera J.
Turnbull, Arran K.
Nitz, Ulrike
Christgen, Matthias
Kreipe, Hans
Kuemmel, Sherko
Bliss, Judith M.
Barry, Peter
Johnston, Stephen R.
Jacobs, Samuel A.
Ma, Cynthia X.
Smith, Ian E.
Harbeck, Nadia
NPJ BREAST CANCER, 2020, 6 (01)
[40] Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer
Thi Truc Anh Nguyen
Lauren M. Postlewait
Chao Zhang
Jane L. Meisel
Ruth O’Regan
Sunil Badve
Kevin Kalinsky
Xiaoxian Li
Breast Cancer Research and Treatment, 2022, 192 : 509 - 516

← 1 2 3 4 5 →